Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To study the relationship between serum circulating free deoxyribonucleic acid (cfDNA), vascular endothelial growth factor A (VEGFA), and the chemotherapy efficacy and prognosis in patients with advanced gastric cancer. A total of 108 patients with advanced gastric cancer who received chemotherapy with oxaliplatin regimen at the 986th Air Force Hospital from June 2018 to June 2020 were selected. All patients received chemotherapy with oxaliplatin regimen. After two cycles of chemotherapy, they were divided into sensitive and insensitive groups according to the Solid Tumor Efficacy Evaluation Standard (RECIST) version 1.1, and their serum cfDNA and VEGFA levels were compared between the two groups; Follow up for 24 months, Kaplan Meier survival curve analysis was performed on the total survival time (OS) of serum cfDNA and VEGFA high expression and low expression groups, and a Cox risk proportional model was used for prognostic multivariate analysis. Results: The serum cfDNA and VEGFA levels in the insensitive group were significantly higher than those in the sensitive group (P<0.05). The median OS of patients with high expression of cfDNA and VEGFA was significantly shorter than that of patients with low expression of cfDNA and VEGFA (P<0.05). Cox regression model univariate analysis showed that gender, age, and location were not associated with the prognosis of advanced gastric cancer (P>0.05), while TNM stage IV, low differentiation, lymph node metastasis, insensitive chemotherapy efficacy, high levels of cfDNA, and VEGFA were significantly correlated with poor prognosis of advanced gastric cancer (P<0.05). Cox regression model multivariate analysis showed that lymph node metastasis, insensitivity to chemotherapy efficacy, and high levels of cfDNA and VEGFA were risk factors for the prognosis of advanced gastric cancer patients (P<0.05). Conclusion: The detection of serum cfDNA and VEGFA levels is helpful for monitoring chemotherapy efficacy and evaluating prognosis in advanced gastric cancer patients. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effect of early internal carotid artery stenting（CAS） on serum lipoprotein-associated phospholipase 2（LP-PLA2） and homocysteine（Hcy） levels in patients with atherosclerotic cerebral infarction. Methods: A total of 86patients with severe carotid artery stenotic cerebral infarction who were diagnosed and treated in the First Affiliated Hospital of Xi’an Jiaotong University from August 2018 to April 2021 were selected as the research subjects. According to the treatment method, the patients were divided into the early CAS group and the control group, 43 cases in each group. The control group were given conservative drug treatment, and after 2 weeks the cerebral infarction was stabilized before surgery. The CAS group was given internal carotid artery stenting after 3-5 days of treatment on the basis of the control group, and the changes of serum Lp-PLA2 and Hcy levels in the two groups were detected. Results: After 7 days of treatment, the total effective rate at 7 days were 97.7 % in the CAS group, which were higher than86.0 % in the control group（P<0.05）. The incidence rates of complications such as hyperperfusion syndrome, cerebral hemorrhage,hypotension, bradycardia in the CAS group were 4.7 % after 7 days of treatment, and there were no cases of hyperperfusion syndrome,cerebral hemorrhage, hypotension, bradycardia ocurred in the control groups that compared were not difference（P<0.05）. The internal carotid artery relative cerebral blood flow and cerebral blood volume in the two groups were higher than those before treatment（P<0.05）,and the CAS group was higher than the control group（P<0.05）. There were no significant difference in the control group before and after treatment（P>0.05）. The levels of Lp-PLA2 and Hcy in serum 7 days after treatment in the two groups were lower than those before treatment（P<0.05）, and those in the CAS group were lower than those in the control group（P<0.05）. Conclusion: The application of early internal carotid artery stenting in patients with atherosclerotic cerebral infarction can inhibit the expression of Lp-PLA2 and Hcy,and improve the hemodynamic changes of patients, thereby promoting the improvement of the therapeutic effect, and having good safety in clinical application. [ABSTRACT FROM AUTHOR]

Objective: 5-HT（5-hydroxytryptamine） is a monoamine neurotransmitter in the brain, playing a critical role in a broad range of biological processes. 5-HT dysregulation has been involved in mental disorders, including anxiety and depression. Despite the importance of 5-HT, our understanding of cell-specific 5-HT signaling is flawed, partly due to the inability to measure 5-HT with a high spatiotemporal solution. Recently developed i SeroSnFR and GRAB5-HT1.0, two genetically encoded 5-HT sensors, have attractive features because of their cell specificity, sensitivity, and excellent spatiotemporal resolution to probe 5-HT dynamics. Our study aims to compare the different properties of i SeroSnFR and GRAB5-HT1.0in response to 5-HT in the mouse brain. It can provide new insights into the optimization of 5-HT sensors and the development of other genetically encoded fluorescent neurotransmitter sensors. It can also help us choose the appropriate sensor based on different scientific issues and explore molecular and cellular mechanisms of neurological diseases. Methods: The i SeroSnFR sensor or GRAB5-HT1.0sensor was expressed in the CA1 neurons of cultured hippocampal slices or DRN of acute mouse brain slices using the Sindbis viral expression system. Then the fluorescence intensity and the fluorescent changes of i SeroSnFR and GRAB5-HT1.0in response to 5-HT drug puff on cultured mouse hippocampal slices or electrical stimuli evoked 5-HT release on acute mouse DRN slices were compared. Results: We found many fluorescence signals in i SeroSnFR-expressing hippocampal CA1 neurons, but the cell boundary was unclear. In comparison, there was a robust green fluorescence signal in GRAB5-HT1.0-expressing hippocampal CA1 neurons. Subsequently, when the CA1 region of mouse hippocampal cultured slices was exposed to 1 μM 5-HT application, the i SeroSnFR sensor almost had no detectable fluorescence changes. However, GRAB5-HT1.0sensor produced robust fluorescence responses. Meanwhile the fluorescence response of the i SeroSnFR is weaker than that of the GRAB5-HT1.0in response to puffed 1 m M 5-HT. In addition, we made Sindbis viral expression of i SeroSnFR or GRAB5-HT1.0sensor and applied electrical stimuli to evoke 5-HT release in the DRN region of acute mouse brain slices. It provoked robust increases in fluorescence in DRN slices expressing GRAB5-HT1.0sensor. On the contrary, the same electrical stimuli almost have no effect in DRN slices expressing the i SeroSnFR sensor.Conclusion: The GRAB5-HT1.0sensor can measure the exogenous 5-HT drug and endogenous 5-HT release with higher affinity and sensitivity in the mouse brain. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To study the quality of life survey and social support and self-medical coping ability in patients with diabetic nephropathy. Methods: 100 patients with diabetic nephropathy who were admitted to the hospital from January 2018 to January 2020 were included in the study. The quality of life of all subjects was assessed through a quality of life questionnaire, and univariate and multivariate Logistic regression analysis was used to identify the related factors affecting the quality of life of patients with diabetic nephropathy. In addition, all subjects in accordance with the quality of life score height were divided into group A (≤80 scores) of 79 cases and group B (> 80 scores) of 21 cases, the differences in social support scores and self-medical coping ability of patients with different quality of life scores were analyzed, and Pearson correlation was used to analyze the relationship between quality of life and social support and self-medical coping ability of patients with diabetic nephropathy. Results: The univariate analysis showed that the quality of life of patients with diabetic nephropathy was related to age, disease course, smoking history, drinking history, hypertension history, take the medicine as directed by your doctor, diet as prescribed by the doctor, and frequency of exercise (all P<0.05). According to multivariate Logistic regression analysis, age > 35 years, disease course > 5 years, with smoking history, drinking history, hypertension history, not taking medication as prescribed, non-prescribed diet, and frequency of exercise ≤3 times/week were all independent risk factors for life quality of patients with diabetic nephropathy (all P<0.05). The scores of social support in group B were higher than those in group A (all P<0.05). The scores of fatalism and avoidance in group B were lower than those in group A, and the scores of other self-medical coping abilities in group B were higher than those in group A (all P<0.05). Pearson correlation analysis showed that the quality of life of diabetic nephropathy patients was positively correlated with the scores of family support, friend support, other people's support, as well as the scores of face, optimism, support, emotional catharsis, palliation and self-dependence, while negatively correlated with the scores of fate and escape (all P<0.05). Conclusion: In clinical work, health education for patients should be strengthened, good daily living programs should be developed for them, and attention should be paid to older patients and patients with a longer course of disease. In addition, the quality of life of diabetic nephropathy patients is closely related to social support and self-medical coping ability. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To study the relationship between serum osteocalcin (BGP), growth hormone releasing peptide (ghrelin) and human cartilage glycoprotein-39 (YKL-40) levels and insulin resistance and cognitive impairment in elderly patients with type 2 diabetes mellitus (T2DM). Methods: 100 elderly patients with T2DM who were admitted to our hospital from January 2018 to December 2019 were seelected as the lesion group. Another 100 healthy elderly volunteers who underwent physical examination in our hospital at the same time were selected as the control group. The levels of BGP, ghrelin and YKL-40, blood glucose, blood lipid and insulin resistance, cognitive impairent and simple mental state examination scale (MMSE) score were compared between the two groups, and correlation analysis was performed. Results: The serum BGP and ghrelin level of the lesion group were lower than those of the control group, while the levels of YKL-40 was higher than that of the control group (P<0.05). Fasting blood glucose (FPG), glycosylated hemoglobin (HbA1c) and insulin resistance index (HOMA-IR) levels in the lesion group were higher than those in the control group, while fasting insulin (fins) levels were lower than those in the control group (P<0.05). There was no significant difference between the pathological group and the control group except for the scores of language and delayed memory (P>0.05), Other MMSE scores were lower than those of the control group (P<0.05). According to Pearson correlation analysis, serum BGP, ghrelin, FPG, HbA1c and HOMA-IR were negatively correlated with fins and MMSE scores (P<0.05), while serum YKL-40 was positively correlated with FPG, HbA1c and HOMA-IR, and negatively correlated with fins and MMSE scores (P<0.05). Conclusions: Serum BGP and ghrelin are significantly lower in elderly T2DM patients, while serum YKL-40 is significantly higher, and the above serological indexes are closely related to insulin resistance and cognitive impairment. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To evaluate the clinical efficacy of Atorvastatin calcium of the treatment on Parkinson's disease (PD) and its mechanism. Methods: Firstly, the effect of atorvastatin calcium on Wnt Signaling and cell apoptosis in MPP+-treated SH-SY5Y cells were analyzed. 66 patients of PD were collected and divided into two groups. The normal treatment group was treated with pramipexole combined with Levodopa and Benserazide Tablets. The Atorva group was treated with Atorvastatin calcium, pramipexole, and Levodopa and Benserazide Tablets. The Hoehn -Yahr Grade, UPDRS scores, and the incidence of adverse reactions were observed. Results: MPP+ treatment induced the down-regulation ofWnt signaling and cell apoptosis in SH-SY5Y cells and the pretreatment of atorvastatin calcium could abrogate this effect. The Hoehn -Yahr Grade were significantly improved in Atorva group compared with normal treatment group after 8 weeks treatment（P＜0.05）. The scores of UPDRS decreased significantly in Atorva group compared with normal treatment group after 8 weeks treatment（P＜0.05）. The incidence of adverse reactions showed no difference in Atorva group and normal treatment group （P＞0.05). Conclusion: Atorvastatin calcium could protect the SH-SY5Y cells from MPP+-induced cell apoptosis via Wnt signaling and PD patients treated with Atorvastatin can improve the motor symptoms, non-motor symptoms. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the clinical Efficacy of shuxuening injection combined with dopamine hydrazine in the treatment of Parkinson's disease and its effect on the blood flow and serum inflammatory factors. Methods: 94 patients with Parkinson's disease who were treated from September 2014 to September 2017 in our hospital were selectd and divided into the control group and the research group according to the random number table method, with 47 cases in each group. The control group was treated with dopamine hydrazine, and the research group was treated with shuxuening injection based on the control group. Then the clinical curative effect, change of UP- DRS II score, UPDRS III score, UPDRS score, cerebral blood flow, the serumInterleukin-1β(IL-1β), interleukin 6 (IL-6), hypersensitive c-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α) levels before and after treatment, and the incidence of adverse reactions were compared between two groups. Results: After treatment, the total effective rate of research group was higher than that of the control group (P<0.05), the UPDRS IIscore, UPDRS IIIscore, UPDRS score, serumlevels of IL-1β, IL-6, hs-CRP and TNF-α of both group were significantly decreased than those before treatment, and the above indicators of research group were significantly lower than those of the control group(P<0.05). The blood flow in the brain area of both groups were significantly higher than those before treatment, which was more obviously in the research group than that in the control group (P<0.05). Nausea, dizziness, insomnia and vomiting were found in both groups, but significant difference was found between two groups (P>0.05). Conclusion: Shuxuening injection combined with dopamine hydrazine is more effective in the treatment of Parkinson's disease than dodohydrazine alone, it can promote the brain blood circula- tion, regulate the brain blood flow, reduce the levels of inflammatory factors. [ABSTRACT FROM AUTHOR]

Objective: To determine the monomer purity and proportion of non-glycosylated heavy chain in reference productsantiCD52 humanized monoclonal antibody. Methods: Using PA800 plus capillary electrophoresis system, Non-reduced CE-SDS were applied to determine monomer purity and reduced CE-SDS were applied to determine non-glycosylated heavy chain in anti-CD52 humanized monoclonal antibody. Results: Average value of monomer purity is 93.57% by Non-reduced CE-SDS in three times, RSD of migration time of main peak and corrected area percent were 0.16% and 0.19% respectively. Average value of heavy chain corrected area percent is 66.89% by reduced CE-SDS in three times, RSD of migration time and corrected area percent of main peak were 0.09% and 0%respectively. Average value of light chain corrected area percent is 32.30% by reduced CE-SDS in three times, RSD of corrected area percent and migration time of main peak were 0% and 0% respectively. Average value of non-glycosylated heavy chain corrected area percent is 0.87% by reduced CE-SDS in three times, RSD of corrected area percent and migration time of main peak were 6.66% and0.27% respectively. Conclusion: The data of using CE-SDS determine the monomer purity and proportion of non-glycosylated heavy chain in anti-CD52 humanized monoclonal antibody displayed a much small RSD, and manifested the result were accurate and reliable. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of Recombinant Human Endostatin Injection combined with lobaplatin on the quality of life and immune function in patients with malignant pleural effusion. Methods: A total of 56 patients with malignant pleural effusion, who were treated in the socond People's Hospital in Jingmen from March 2015 to March 2017. were selected and divided into study group (n=28) and control group (n=2S) according to the different treatment methods. The control group was given chemotherapy with lobaplatin. and the study group was treated with Recombinant Human Endostatin Injection combined with lobaplatin. The changes of the quality of life, the changes of immune function before and after treatment, the clinical effect and the occurrence of adverse reactions were compared between the two groups. Results: Improvement rate of quality of life of the patients in the study group was higher than that of the control group (p<0.05). Before treatment, there was no significant difference in the contents of immune function indexes between the two groups by statistical analysis (P>0.05). Compared with those before treatment, the contents of CD3+. CD4+. CD4+CDS+and XK in the two groups 4 weeks after treatment were increased, while the content of CD8+was decreased, the contents of CD3+. CD4+. CD4/CD8+ and NK in the study group were higher than those in the control group, and the content of CDS+ in the study group was lower than that in the control group (p<0.05)- The total effective rate of the study group was 78.57%. compared with the 46.43% of the control group, the difference was statistically significant (P<0.05)- There was no significant difference in the incidence of cardiac reactions, vomiting, nausea.thrombocytopenia, aleucocytosis. anemia and fatigue between the two groups (p<.05)- Conclusion: Recombinant Human Endostatin Injection combined with lobaplatin has a good effect in the treatment of malignant pleural effusion. It can improve the quality of life of the patients, improve the immune function, and it will not increase the adverse reaction of the patients, which is worthy of clinical promotion. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the curative efficacy of combined use of dexamethasone palmitate, vitamin B12 and lidocaine in the treatment of knee osteoarthritis and its effects on the serum levels of interleukin-1 (IL-1), matrix metalloproteinase-3 (MMP-3) and matrix metalloproteinase-1 (TIMP-1). Methods: 84 patients with osteoarthritis of knee were selected from August 2014 to July 2015 in Sixth Affiliated Hospital of Xinjiang Medical University and divided into the observation group and the control group according to the order of admission, 42 cases in each group. The observation group was given intra-articular injection of dexamethasone palmitate, vitamin B12 and lidocaine, and the control group was treated with traditional Chinese medicine. The clinical efficacy was evaluated after treatment. The changes of serum IL-1, MMP-3, TIMP-1 levels and visual analogue (VAS) score were compared before and at 1 months after treatment. Results: After treatment,the total effective rate of observation group was significantly higher than that of the control group (P＜0.05), the serum levels ofIL-1, MMP-3 levels and VAS score were significantly lower than those before treatment, serum TIMP-1 level was obviously higher than that before treatment(P ＜0.05), the serum levels of IL-1, MMP-3 levels were significantly lower in the observation group than those of the control group, while the serum TIMP-1 level was obviously higher than(P＜0.05) Conclusion: Intra-articular injection with dexamethasone palmitate, vitamin B12 and lidocaine could effectively decrease the levels of serum IL-1 and MMP-3, increase the level ofTIMP-1, and relieve the pain in the patients with knee osteoarthritis. [ABSTRACT FROM AUTHOR]

Objective: To evaluate the effect of Ubenimex oil the immune function of patients with advanced non-small cell lung cancer (NSCLC). Methods: 78 patients with NSCLC who were in our hospital from January 2014 to January 2016 were selected, they were divided into control group and experimental group according to the random number table method. 39 cases in easli group, the control group was received conventional radiotherapy and chemotherapy, the experimental group was Heated with Ubenimex on the basis of conventional radiotherapy and chemotherapy. The immune function of the two groups before and after treatment should be observed and compared. Results: Compared with before treatment, the levels of serum soluble interleukin -2 receptor (sIL-2R). interleukin -6 (IL-6). interleukin -8 (IL-S) and tumor necrosis factor (TNF-α) were decreased in the experimental group after treatment, and the experimental group was lower than that of the control group, the difference was statistically significant (P<0.05). The proportion of T cell subsets (CD3+. C'D4+) and NK cells in peripheral blood and the ratio of CD47C'D8+ of the experimental group were increased compared with before treatment, and the experimental group was higher than that in the control group (P<0.05). The proportion of CD8+ has declined.and the experimental group was lower than the control group, the difference was statistically significant (P<0.05). Conclusion: The T cell subsets. NK cell content in peripheral blood and the levels of sIL-2R. IL-6. IL-8. TNF-α in serum can reflect the immune status of the patients. Ubenimex combined with radiotherapy and chemotherapy can effectively improve the immune function of patients with advanced NSCLC. can be used as adjuvant medicine. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To observe the clinical curative effects of the medial sural artery perforator island musculocutaneous flap on proximal tibial osteomyelitis combined with bone exposure. Methods: Between Janury 2013 and June 2015, the medial sural artery perforator island musculocutaneous flap were used to reconstruct proximal tibial osteomyelitis combined with bone exposure in 15 patients at our institute. The areas of defect ranged from5 cm× 4 cm to 8 cm× 7 cm, Flap sizes ranged from6 cm× 5 cmto 9 cmx 8 cm. The flap survival rate, complication, the function of knee and ankle joint, appearance of satisfaction were followed up. Results: Flaps survived in all patients cases．the muscle flaps in 14 cases healed in phaseⅠ and those in 1 cases healed in phaseⅡ . There was no recurrence in the follow-up of 6 months to 18 months. There were no stiffness of the joint. According to the modified ASAMI criteria for bone healing, 10 cases were excellent, 4 good, one moderate, zero poor. Conclusions: The medial sural artery perforator island musculocutaneous flap is an effective treatment for proximal tibial osteomyelitis combined with bone exposure. [ABSTRACT FROM AUTHOR]

Objective: To analyse the role of aspirin in down-regulation the Wnt signaling which activated by morphine addiction. Many studies have revealed that Wnt signaling activated in morphine addiction rats models. Methods: Many technologies such as Immunofluorescence. western blot were canied out. We also used the Luciferase test to study the downstream gene change in Wnt signaling after morphine addiction with or without aspirin pretreatment. Results: We found that the level of β-catenin increased in chronic morphine addiction group. However, the use of 6h aspirin before adding morphine leads to the down-regulation of β-catenin. Conclusions: Our study identified that aspirin can inhibited the Wnt signaling which activated after chronic morphine addiction and this may be important in the cure of morphine addiction. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)